AngioDynamics (NASDAQ:ANGO) Issues FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of ($0.38)-($0.34) for the period, compared to the consensus estimate of ($0.40). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $283.86 million. AngioDynamics also updated its FY 2025 guidance to -0.380–0.340 EPS.

AngioDynamics Stock Up 37.7 %

Shares of NASDAQ ANGO opened at $12.94 on Thursday. AngioDynamics has a 12-month low of $5.26 and a 12-month high of $13.13. The firm’s 50-day simple moving average is $7.99 and its 200 day simple moving average is $7.34. The company has a market cap of $525.80 million, a price-to-earnings ratio of -2.12 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. During the same period in the prior year, the business earned ($0.05) earnings per share. AngioDynamics’s quarterly revenue was down .1% on a year-over-year basis. On average, equities analysts expect that AngioDynamics will post -0.41 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on ANGO shares. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research note on Tuesday, December 10th. Canaccord Genuity Group lowered their price objective on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.